Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent breast cancer.

Key facts

Study ID

NCT00004182

Run by

Northwestern University

Starts

1999-10-01

Expected to finish

2000-04-01

Last updated by the study team

2012-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University Medical Center — Stanford, California, United States
• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.